
    
      This study is conducted using a randomised, double-blind, placebo controlled parallel group
      design, after a single-blind placebo period. Primary insomnia patients aged over 55 will be
      screened for entry into the study.

      After placebo run-in period, Patients will enter a 3 weeks double-blind treatment period.

      Primary parameter is quality of sleep, secondary parameters are including getting to sleep,
      awakening from sleep, behavior following wakefulness, quality of day and night, sleep latency
      and quality of life.
    
  